You are here
The Ebola Epidemic: Is There a Way Out?
According to the International Union of Immunology Societies (IUIS), based in Berlin, Germany, the survival rate for Ebola infection is around 30%, suggesting that immunity to the disease is possible. Experimental treatments and vaccines against Ebola exist but have not yet been tested in large groups for safety and efficacy (phase II trials).
The IUIS has published a statement in its official journal, Frontiers in Immunology, calling for urgent and adequate funding of vaccine candidates in clinical trials and speedy implementation of immunization in African countries.
“The current Ebola outbreak is an unprecedented disaster for humans. This virus cunningly hijacks the human immune system with devastating effects. Without blocking transmission, Ebola may become endemic,” said lead author Professor Clive Gray of the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa. “Efforts are being made on health communication in order to prevent the spread of this virus from person to person. This is essential but not enough. Stakeholders need to work together to accelerate the roll-out of vaccines and therapies,” Gray stated.
According to the IUIS paper, vaccination will be a vital additional strategy. The authors explain that although no licensed vaccines are on the market, “significant progress” has been made in recent years and especially in the last few months.
Among the promising vaccines being tried today, the paper mentions the Cad3 Ebola vaccine developed using chimpanzee adenovirus. This vaccine was found to protect animals with a single dose and is currently undergoing phase I trials. Another promising vaccine candidate is rVSV-ΔG-ZEBOV, which has proven to be safe and effective in non-human primates, with no major toxicities. Phase I trials of this vaccine started in October.
Commenting on the need for a vaccination strategy, Professor Marylyn Addo, of the University Medical Center in Hamburg, Germany, explained: “The fact that the current outbreak of Ebola is through a single strain with low mutability suggests that vaccine strategies could be easily achievable. Understanding how immunity works in survivors of Ebola may further contribute to strategic vaccine design and optimization.
Addo concluded: “We need to speed up the development process in order to advance clinical testing and, ultimately, the deployment of effective vaccines. However, despite the urgency of the situation, the safety of the vaccines for recipients needs to be ensured and cannot be compromised.”
Alongside vaccination (to prevent infection), the IUIS paper says that experimental therapies are also available to treat people who are already infected with the virus. ZMapp, for example, combines antibodies that cling to the virus and allow the immune system to clear it. The drug has been tried on animals and humans with different outcomes. ZMapp, however, is no longer available, so it cannot be tested further.
Other therapeutic approaches include siRNA (also known as TKM-Ebola) and Favipiravir (T705). “These drugs need to be tried for efficacy and safety, but currently we do not have time to conduct traditional studies,” said Professor Reinhold Schmidt, Director of the Centre of Internal Medicine at the University of Hannover in Germany.
The IUIS paper calls for a speedy roll-out of a human vaccine for Ebola. Schmidt continued: “Of course, we do not overrule the need for trials to ensure safety, but IUIS is calling on authorities to speed up the process by A) performing parallel animal safety and immunogenicity studies alongside human phase I clinical trials with small sets of volunteers to assess safety and optimal dosage, and B) rapidly designing and implementing phase II clinical trials.”
“Time is not on our side,” Schmidt added. “Funding is urgently needed, as well as a more flexible and speedy process to make vaccines available to populations at greatest risk, in order to halt this devastating Ebola outbreak.”
Source: EurekAlert; October 27, 2014.